UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

41.40 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

July 27, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

July 25, 2023

From UroGen Pharma Ltd.

Via Business Wire

Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation

July 10, 2023

From UroGen Pharma Ltd.

Via Business Wire

Recap: UroGen Pharma Q1 Earnings ↗

May 11, 2023

Via Benzinga

UroGen Pharma Earnings Preview ↗

March 15, 2023

Via Benzinga

UroGen Pharma's Return On Capital Employed Overview ↗

December 20, 2022

Via Benzinga

UroGen Pharma to Host UGN-102 Data Event on July 27, 2023

July 06, 2023

From UroGen Pharma Ltd.

Via Business Wire

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

June 20, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 09, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences

June 02, 2023

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For May 11, 2023 ↗

May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...

Via Benzinga

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 11, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

May 04, 2023

From UroGen Pharma Ltd.

Via Business Wire

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

May 01, 2023

From UroGen Pharma Ltd.

Via Business Wire

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

April 30, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

April 25, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

March 16, 2023

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For March 16, 2023 ↗

March 16, 2023

Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.

Via Benzinga

UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023

March 09, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences

March 01, 2023

From UroGen Pharma Ltd.

Via Business Wire

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

February 15, 2023

From UroGen Pharma Ltd.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023 ↗

February 08, 2023

Via Benzinga

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

January 11, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

December 19, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

December 02, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer

December 01, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference

November 21, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma

November 14, 2022

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.